Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma HELP
Based on 34,116 articles published since 2008
|||| 19 

These are the 34116 published articles about Melanoma that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
126 Editorial Novel T-cell-based vaccines via arming polyclonal CD4 2016

Xu, Aizhang / Freywald, Andrew / Xiang, Jim. ·Cancer Research, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada. · Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. · Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. ·Immunotherapy · Pubmed #27993084.

ABSTRACT: -- No abstract --

127 Editorial New Does Not Always Mean Better: Isolated Limb Perfusion Still Has a Role in the Management of In-Transit Melanoma Metastases. 2016

Puzanov, Igor / Skitzki, Joseph. · ·Oncology (Williston Park) · Pubmed #27987195.

ABSTRACT: -- No abstract --

128 Editorial Relation of statin use with non-melanoma skin cancer: Prospective results from the Women's Health Initiative. 2016

Wang, Ange / Tang, Jean Y / Stefanick, Marcia L. ·Stanford University School of Medicine, Stanford, CA, USA angewang@stanford.edu. · Stanford University School of Medicine, Stanford, CA, USA. · Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA. ·Womens Health (Lond) · Pubmed #27885164.

ABSTRACT: -- No abstract --

129 Editorial Randy Lomax, 1947-2016. 2016

Herlyn, Meenhard. ·The Wistar Institute, Philadelphia, PA. ·Pigment Cell Melanoma Res · Pubmed #27860381.

ABSTRACT: -- No abstract --

130 Editorial Detection of skin cancer odours using dogs: a step forward in melanoma detection training and research methodologies. 2016

Elliker, K R / Williams, H C. ·No affiliation. k.r.elliker.98@cantab.net. · Centre of Evidence Based Dermatology, University of Nottingham, King's Meadow Campus, Lenton Lane, Nottingham, NG7 2NR, U.K.. hywel.williams@nottingham.ac.uk. ·Br J Dermatol · Pubmed #27790682.

ABSTRACT: -- No abstract --

131 Editorial BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. 2016

Dronca, Roxana S / Mansfield, Aaron S / Park, Sean S / Dong, Haidong. ·Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. · Division of Radiation Oncology, Mayo Clinic, Rochester, MN, USA. · Department of Immunology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. · Department of Urology, Mayo Clinic, Rochester, MN, USA. ·Immunotherapy · Pubmed #27784186.

ABSTRACT: -- No abstract --

132 Editorial [Progress and challenges in the management of atypical melanocytic lesions]. 2016

Avril, Marie-Françoise. ·Service de dermatologie, hôpital Cochin, Université Paris Descartes, AP-HP, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. Electronic address: marie-francoise.avril@aphp.fr. ·Ann Pathol · Pubmed #27751404.

ABSTRACT: -- No abstract --

133 Editorial The future of melanoma therapy: developing new drugs and improving the use of old ones. 2016

Palumbo, Giuliano / Di Lorenzo, Giuseppe / Ottaviano, Margaret / Damiano, Vincenzo. ·Medical Oncology Unit, Department of Clinical Medicine, Federico II University, 80138 Naples, Italy. ·Future Oncol · Pubmed #27715206.

ABSTRACT: -- No abstract --

134 Editorial Resistance patterns to anti-PD-1 therapy in metastatic melanoma. 2016

Ozgun, Alpaslan / Sondak, Vernon K / Markowitz, Joseph. ·Department of Cutaneous Oncology, Moffitt Cancer Center, and Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. · Department of Cutaneous Oncology, Moffitt Cancer Center, and Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. joseph.markowitz@moffitt.org. ·Chin Clin Oncol · Pubmed #27701871.

ABSTRACT: -- No abstract --

135 Editorial Molecular testing to differentiate melanoma from benign nevi: The gold standard limitation. 2016

Bitterman, Avi. ·Jefferson Medical College (Sidney Kimmel Medical College), Philadelphia, Pennsylvania; Department of Medicine, Jersey Shore University Medical Center, Neptune City, New Jersey. Electronic address: avi.bitterman@jefferson.edu. ·J Am Acad Dermatol · Pubmed #27646748.

ABSTRACT: -- No abstract --

136 Editorial Commentary: Factors associated with positive or equivocal margins of atypical intraepidermal melanocytic proliferations: True conundrum or imprecise language? 2016

Grant-Kels, Jane M. ·Department of Dermatology, University of Connecticut, Farmington, Connecticut. Electronic address: grant@uchch.edu. ·J Am Acad Dermatol · Pubmed #27646738.

ABSTRACT: -- No abstract --

137 Editorial An Evolving Approach to the Detection of Melanoma and Other Skin Cancers Using In Vivo Reflectance Confocal Microscopy. 2016

Scope, Alon / Marchetti, Michael A. ·Department of Dermatology, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel2Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. · Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ·JAMA Dermatol · Pubmed #27580064.

ABSTRACT: -- No abstract --

138 Editorial Disparate clinical activity of PD-1 blockade in melanoma subtypes: Know thy enemy! 2016

Bhatia, Shailender / Margolin, Kim. ·Department of Medicine/Medical Oncology, University of Washington, Seattle, Washington. sbhatia@uw.edu. · Fred Hutchinson Cancer Research Center, Seattle, Washington. sbhatia@uw.edu. · Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California. ·Cancer · Pubmed #27533794.

ABSTRACT: -- No abstract --

139 Editorial The Case for Skin Cancer Screening With Total-Body Skin Examinations. 2016

Nahar, Vinayak K / Mayer, Jonathan E / Grant-Kels, Jane M. ·Department of Dermatology, School of Medicine, University of Mississippi Medical Center, Jackson2Department of Health, Physical Education, and Exercise Science, School of Allied Health Sciences, Lincoln Memorial University, Harrogate, Tennessee3Department. · Department of Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. · Department of Dermatology, University of Connecticut Health Center and School of Medicine, Farmington. ·JAMA Oncol · Pubmed #27459540.

ABSTRACT: -- No abstract --

140 Editorial Visual Inspection and the US Preventive Services Task Force Recommendation on Skin Cancer Screening. 2016

Tsao, Hensin / Weinstock, Martin A. ·Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Boston. · Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, Rhode Island3Division of Dermatology, Veterans Affairs Medical Center, Providence, Rhode Island. ·JAMA · Pubmed #27458944.

ABSTRACT: -- No abstract --

141 Editorial Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma. 2016

Loeb, Stacy / Stattin, Pär. ·Department of Urology, Population Health, and Laura & Isaac Perlmutter Cancer Center, New York University, NY, USA. Electronic address: stacyloeb@gmail.com. · Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; Department of Surgery and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden. ·Eur Urol · Pubmed #27436160.

ABSTRACT: -- No abstract --

142 Editorial What is the OPTiMal Way to Manage In-Transit Disease? 2016

Olino, Kelly / Tyler, Douglas S. ·Department of Surgery, The University of Texas Medical Branch, Galveston, TX, USA. · Department of Surgery, The University of Texas Medical Branch, Galveston, TX, USA. dstyler@utmb.edu. ·Ann Surg Oncol · Pubmed #27380046.

ABSTRACT: -- No abstract --

143 Editorial The melanoma field with dendritic roots. 2016

Aplin, Andrew E. · ·Pigment Cell Melanoma Res · Pubmed #27320440.

ABSTRACT: -- No abstract --

144 Editorial Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma. 2016

Swetter, Susan M. ·Dermatology Service, Department of Veterans Affairs Palo Alto Health Care System, Palo Alto, California; Department of Dermatology, Pigmented Lesion and Melanoma Program, Stanford University Medical Center and Cancer Institute, Stanford, California. Electronic address: sswetter@stanford.edu. ·J Am Acad Dermatol · Pubmed #27317056.

ABSTRACT: -- No abstract --

145 Editorial Predicting the Risk of Melanoma. 2016

Emery, Jon D / Usher-Smith, Juliet A / Walter, Fiona M. ·Department of General Practice, Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne, Melbourne, Australia2Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. · Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom. ·JAMA Dermatol · Pubmed #27275772.

ABSTRACT: -- No abstract --

146 Editorial Advances in intracellular Ca(2+) signalling. 2016

Parekh, Anant B. ·Department of Physiology, Anatomy and Genetics, Parks Road, Oxford OX1 3PT, UK. ·J Physiol · Pubmed #27246547.

ABSTRACT: -- No abstract --

147 Editorial National Institute for Health and Care Excellence melanoma guidelines: good news for patients but challenging to implement. 2016

Schofield, J K / Robinson, R / Reeken, S / Jackson, R. ·United Lincolnshire Hospitals NHS Trust, Lincoln County Hospital, Lincoln, U.K.. j.k.schofield@herts.ac.uk. · Harrogate and District NHS Foundation Trust, Harrogate, U.K. · Kingston Hospital NHS Foundation Trust, London, U.K. · Patient Member, NICE Guideline Development Group. ·Br J Dermatol · Pubmed #27206352.

ABSTRACT: -- No abstract --

148 Editorial Introduction. 2016

Smith, M Timothy / Wick, Mark R. · ·Semin Diagn Pathol · Pubmed #27199076.

ABSTRACT: -- No abstract --

149 Editorial Prediction is Difficult, Especially About the Future: Clinical Prognostic Tools in Melanoma. 2016

Sondak, Vernon K / Messina, Jane L. ·Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. vernon.sondak@moffitt.org. · Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. vernon.sondak@moffitt.org. · Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. · Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. · Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA. · Departments of Pathology and Cell Biology, Dermatology and Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. ·Ann Surg Oncol · Pubmed #27198510.

ABSTRACT: -- No abstract --

150 Editorial Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma. 2016

Spain, Lavinia / Larkin, James. ·Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK. ·Immunotherapy · Pubmed #27197536.

ABSTRACT: -- No abstract --

Back · Next